ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M

ENDRA Life Sciences Inc.

2025-Q3 EPS reported -$82.14 vs consensus -$1.99 ▼ miss (-4029.7%)

Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).
Operating expenses fell 52% to $1.5M on $3.1M in annualized cost savings from restructuring.
Cash and cash equivalents were $4.7M as of September 30, 2024.
Accelerated enrollment in global pilot study for TAEUS liver fat assessment; activated site at LMU Germany.
Added AI/ML/DL features to TAEUS; IP portfolio expanded to 82 issued patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.